Patheon has completed its expansion of services using a new Intermediate Scale Processing Suite (ISPS) at its Cincinnati, OH facility. The ISPS provides increased manufacturing capacity, bridging the company's development and commercial scale facilities.
   
The ISPS equipment includes an intermediate scale Diosna-P300 high shear granulator coupled with Niro-MP4 fluid bed dryer with solvent and high potency compound handling capabilities. This suite will allow the production of batch sizes ranging from 35-115 kg. The ISPS will allow the company to provide development, clinical, registration, scale-up, validation and commercial services to customers. The ISPS provides greater flexibility in scheduling experiments on a larger scale, using less active pharmaceutical ingredients (API) compared to commercial scale, according to the company.

Terry Novak, Patheon's president, North America and chief marketing officer, stated, "The ISPS provides us with another valuable service to address the unique needs of our customers. By adding this equipment we will be able to reduce time and resources it takes to moving a new product though development."

Dr. Christophe Berthoux has been named executive vice president, global sales and marketing and chief commercial officer, Charles River Laboratories. In this newly created position, Dr. Berthoux will lead the global realignment of the company's sales and marketing organization, with the goal of enhancing the company's interface with its customers.

"Given Dr. Berthoux's scientific and business training, his in-depth customer knowledge, as well as his considerable sales and marketing experience, I am confident that he will provide extraordinary levels of leadership in driving this newly created global organization," said James C. Foster, chairman, president and chief executive officer of Charles River.

Muhammad Asif, Ph.D. has been named director of analytical development, and Paul Maffuid, Ph.D. has been named senior vice president of operations, Irvine Pharmaceutical Services.

Dr. Asif has more than 17 years of experience including supporting the development of pharmaceutical products through his various roles at MannKind Corp., DEY, L.P. (an associate of Merck KGaA), Wyeth, and Fujisawa, USA. His expertise ranges from analytical method development and validation to extractables/leachables, product characterization studies and preparation of analytical portions of the CMC sections of INDs, NDAs and ANDAs.

Dr. Maffuid has 20 years of experience in the pharmaceutical industry having worked at various companies, including Arena Pharmaceuticals, Inc., Magellan Laboratories, Inc., Cabrillo Laboratories, Amylin Pharmaceuticals, Inc., Glaxo research, California Biotechnology and Syntex, Inc. He is a member of the American Association of Pharmaceutical Scientists and the American Chemical Society, and has authored several publications.

Irvine Pharmaceutical Services welcomes Dr. Maffuid and Dr. Asif as part of the company's ongoing efforts to continually improve its client services through employment of unparalleled professionals. "I am proud to have Dr. Maffuid and Dr. Asif join our staff," said Assad J. Kazeminy, chief executive officer and founder of Irvine Pharmaceutical Services. "Each brings an impressive depth of knowledge and experience, which I am confident will prove invaluable to our current and future clients."

News from our sister sites